Adhera Therapeutics Announces Appointment of Dr Zahed Subhan to Board of Directors


Baton Rouge, LA, November 08, 2021 (GLOBE NEWSWIRE) – Adhera Therapeutics, Inc. (OTCPK: ATRX) (“Adhera” or the “Company”), a clinical-stage biopharmaceutical company, is pleased to announce the appointment of Zahed Subhan, BS MS PhD MBA LLB, to the board of directors of the company.

Dr Subhan is an international pharmaceutical and biotechnology executive with over 30 years of experience in the United States, United Kingdom, European Union and Asia. He is fully proficient in all phases of drug development and has expertise in the therapeutic areas of neurology, psychiatry, oncology, cardiovascular disease, urology and metabolic disease. Among other positions during his career, Dr Subhan has served as CEO, NuEvolution A / S, Copenhagen, Denmark (acquired by Amgen); Commercial Director, Gemini Genomics Inc, UK / US (acquired by Sequenom Inc.); Head of Business Development and Marketing and Director of European Marketing, DuPont Pharmaceuticals (acquired by Bristol Myers Squibb); Product Manager and New Product Manager, GlaxoSmithKline; and head of clinical research, Sanofi-Aventis.

“We welcome Dr. Subhan to our Board of Directors and look forward to his decades of experience in drug development, business development and capital markets as we advance our investigational drugs throughout the clinical process, ”commented Andrew Kucharchuk, Managing Director. Officer at Adhera Therapeutics. “We believe that attracting a person of their caliber speaks volumes about the quality of our drug candidates. His credentials are impeccable, his international experience invaluable and he has intimate experience with MLR-1023, knowledge that will be instrumental in structuring and conducting our planned Phase 2b clinical trial in type 1 diabetes. ”

“I am delighted to join the Adhera leadership team and play a role in advancing a compelling pipeline in international and domestic markets to address certain areas of unmet medical need and create value for the company. ‘business,’ Dr Subhan said. “The world needs innovation to bring new solutions to market for notoriously difficult conditions like type 1 diabetes, NASH and Parkinson’s disease and I think that while there is a lot of work to be done , repositioning the MLR-1023 and MLR-1019 is just that. type of innovation that justifies additional clinical studies.

Dr Subhan brings to Adhera:

  • Over 30 years of experience in drug discovery, clinical development and biopharmaceutical business development.

  • Experience in executing major pharmaceutical launches in the fields of neurology, psychiatry and cardiovascular therapy.

  • Expertise in starting up biopharmaceutical companies, setting up business infrastructure, managing strong growth and carrying out business acquisitions and sales (M&A).

  • Decades of scientific and regulatory knowledge required to support successful submissions to FDA (US) and EMA (EU) agencies at all stages of drug / device development.

  • Extensive experience in raising venture capital funds for emerging biopharmaceutical and life sciences companies.

Dr Subhan is also currently Clinical Professor / Teacher at Drexel University, PA, USA.

He received his BA in Pharmacology from the University of Sunderland, School of Pharmacy, UK; MS in Applied Psychology and Neuroscience from Aston University, UK; PhD in Psychopharmacology from Leeds University, UK (Russell Group: Top 20 Research University in UK); MBA Marketing from the University of Bradford, UK; and LLB Law from the University of West London.

Dr Subhan is the author of over 40 peer-reviewed articles published in academic journals on the topics of clinical pharmacology and business.

Adhera Therapeutics, Inc.
Andrew Kucharchuk
Chief executive officer
[email protected]


Comments are closed.